Hims & Hers: A Strategic Pivot Amidst Intensifying Market Pressures

Hims & Hers revenue surged 59% to $2.35B in 2025, but free cash flow plummeted as it shifts from compounded drugs to branded Novo Nordisk partnership, facing new pricing pressure from Eli Lilly.

The telehealth company Hims & Hers is navigating a significant strategic transformation. This shift coincides with a period of heightened competition and evolving market dynamics, placing its business model and financial performance under close scrutiny.

Financial Performance and Internal Sentiment

The company's latest annual results for 2025 present a dual narrative. Revenue surged by 59% to reach $2.35 billion. However, this top-line growth was accompanied by a sharp contraction in free cash flow, which fell to $57.4 million from $198.3 million in 2024. Market observers attribute this decline to the costs associated with the company's ongoing transition toward distributing branded pharmaceuticals.

Internal trading activity reveals mixed signals from leadership. In March, Chief Financial Officer Oluyemi Okupe and Chief Operating Officer Michael Chi sold shares. Chi's transaction involved 97,289 shares at an average price of $24.69. Conversely, a notable purchase was made in February by U.S. Representative Tony Wied (R-WI), who acquired stock valued between $500,000 and $1 million.

A Fundamental Shift in Strategy

A core element of the company's restructuring is its exit from the market for compounded GLP-1 medications. This move follows the U.S. Food and Drug Administration's declaration that the shortage of semaglutide has ended. Instead of compounding, Hims & Hers is now forging a partnership with the pharmaceutical giant Novo Nordisk to offer branded products.

This strategic pivot, however, introduces new challenges. Transitioning from proprietary compounded products to licensed brand-name drugs like Wegovy and Ozempic is expected to exert pressure on the company's profit margins.

Mounting Competitive and Pricing Pressures

The competitive landscape for weight-loss medications intensified significantly in early April. On April 2, Novo Nordisk—Hims & Hers' new partner—released data from its ORION study. The results showed that an oral version of Wegovy (semaglutide 25 mg) achieved an average weight reduction of 16.6%. This performance surpassed the 11.2% to 12.4% reduction reported for Eli Lilly's rival oral drug, Foundayo (orforglipron), in clinical trials.

Shortly thereafter, on April 6, Eli Lilly launched Foundayo directly to consumers. The drug is priced at $149 per month through its LillyDirect platform, a cost supported by an agreement with the White House. This aggressive self-pay pricing model directly challenges the subscription frameworks of telehealth providers, including Hims & Hers.

Analyst Outlook and Market Valuation

The consensus among market analysts reflects a cautious stance. The current average rating for Hims & Hers shares is "Hold," with price targets ranging from $24.15 to $31.71. For the 2026 fiscal year, analysts project a revenue growth rate of approximately 17%, a notable deceleration from the previous year's 59% increase.

Trading at $19.14, the stock has declined roughly 43% since the start of the year. While the analyst price targets suggest potential upside from current levels, the prevailing sentiment is one of measured expectation rather than unbridled optimism, as the company executes its complex strategic overhaul.